Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

Lifeward Ltd. announced shareholder approval for a strategic partnership with Oramed Pharmaceuticals, integrating Oramed's POD™ oral delivery technology platform. The deal provides Lifeward with up to $47 million in capital while allowing the company to diversify from its core medical technology business into biotechnology. Oramed will manage and fund the POD™ platform's clinical development, while Lifeward maintains focus on profitability from its existing ReWalk® and AlterG® product lines.

03/13/2026, 8:00 AM • GlobeNewswire

Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments

Oramed Pharmaceuticals received an $18 million payment from Scilex Holdings, closing out option agreement obligations and bringing total returns to $118 million on its original $99.5 million investment. The company's board approved a $0.25 per share cash dividend (~$10.5 million aggregate) to be paid on January 26, 2026. Oramed retains $39 million in outstanding debt, convertible notes, warrants, and royalty interests with Scilex.

01/07/2026, 8:55 AM • Benzinga

ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS

Oramed Pharmaceuticals announced a Rights Plan to protect against hostile takeovers, distributing one common stock purchase right per outstanding share, with rights becoming exercisable if a person/group acquires 15% or more of outstanding stock.

11/17/2025, 8:50 AM • Benzinga